###begin article-title 0
###xml 58 63 54 59 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PCSK9</italic>
###xml 151 152 147 148 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fn" rid="FN1">*</xref>
Hepatocyte Nuclear Factor 1alpha Plays a Critical Role in PCSK9 Gene Transcription and Regulation by the Natural Hypocholesterolemic Compound Berberine*
###end article-title 0
###begin p 1
###xml 140 145 140 145 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PCSK9</italic>
###xml 150 154 150 154 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LDLR</italic>
###xml 361 366 361 366 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PCSK9</italic>
###xml 732 737 732 737 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PCSK9</italic>
###xml 913 918 913 918 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PCSK9</italic>
###xml 994 999 994 999 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PCSK9</italic>
###xml 1115 1120 1111 1116 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PCSK9</italic>
###xml 1336 1341 1332 1337 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PCSK9</italic>
###xml 1474 1479 1466 1471 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PCSK9</italic>
###xml 1736 1741 1728 1733 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PCSK9</italic>
PCSK9 is a natural inhibitor of LDL receptor (LDLR) that binds the extracellular domain of LDLR and triggers its intracellular degradation. PCSK9 and LDLR are coordinately regulated at the transcriptional level by sterols through their promoter-imbedded sterol response elements (SRE) and co-induced by statins. Identification of regulatory networks modulating PCSK9 transcription is important for developing selective repressors of PCSK9 to improve statin efficacy by prolonging the up-regulation of LDLR. Interestingly, the plant-derived hypocholesterolemic compound berberine (BBR) up-regulates LDLR expression while down-regulating PCSK9. In our investigations to define mechanisms underlying the transcriptional suppression of PCSK9 by BBR in HepG2 cells, we have identified a highly conserved hepatocyte nuclear factor 1 (HNF1) binding site residing 28 bp upstream from SRE as a critical sequence motif for PCSK9 transcription and its regulation by BBR. Mutation of the HNF1 site reduced PCSK9 promoter activity >90%. A battery of functional assays identified HNF1alpha as the predominant trans-activator for PCSK9 gene working through this sequence motif. We further provide evidence suggesting that HNF1 site works cooperatively with SRE as HNF1 mutation significantly attenuated the activity of nuclear SREBP2 to transactivate PCSK9 promoter. Finally, we show that a coordinate modest reduction of HNF1alpha and nuclear SREBP2 by BBR led to a strong suppression of PCSK9 transcription through these two critical regulatory sequences. This is the first described example of SREBP pairing with HNF1 to control an important regulatory pathway in cholesterol homeostasis. This work also provides a mechanism for how BBR suppresses PCSK9 transcription.
###end p 1
###begin p 2
###xml 120 125 120 125 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PCSK9</italic>
###xml 126 127 126 127 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
###xml 126 127 126 127 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fn" rid="FN2"><sup>2</sup></xref>
###xml 232 236 232 236 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LDLR</italic>
###xml 251 255 251 255 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">apoB</italic>
###xml 258 259 258 259 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B1">1</xref>
###xml 259 259 259 259 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B2"/>
###xml 260 261 260 261 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B3">3</xref>
###xml 337 338 337 338 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B4">4</xref>
###xml 340 341 340 341 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B5">5</xref>
###xml 428 429 428 429 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B6">6</xref>
###xml 508 509 508 509 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B7">7</xref>
###xml 509 509 509 509 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B8"/>
###xml 510 511 510 511 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B9">9</xref>
###xml 688 690 688 690 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B10">10</xref>
###xml 690 690 690 690 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B11"/>
###xml 691 693 691 693 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B12">12</xref>
###xml 18 23 <span type="species:ncbi:9606">human</span>
###xml 288 294 <span type="species:ncbi:9606">humans</span>
Recent studies of human genetics and genome-wide screens have identified proprotein convertase subtilisin/kexin type 9 (PCSK9)2 as the third gene associated with autosomal dominant familial hypercholesterolemia, after LDL receptor (LDLR) and apoB100 (apoB) (1-3). In hypercholesterolemic humans, "gain of function" mutations were found (4, 5), whereas in hypocholesterolemic subjects "loss of function" mutations were detected (6). The function of PCSK9 as a secreted serine protease degrading hepatic LDLR (7-9) directly correlates with its tight association with plasma cholesterol levels and provides a new therapeutic target to combat hypercholesterolemia and coronary heart disease (10-12).
###end p 2
###begin p 3
###xml 97 99 97 99 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B13">13</xref>
###xml 336 338 336 338 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B13">13</xref>
###xml 340 342 340 342 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B14">14</xref>
###xml 432 434 432 434 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B15">15</xref>
###xml 436 438 436 438 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B16">16</xref>
PCSK9 is predominantly expressed in adult liver hepatocytes and in small intestinal enterocytes (13). It is synthesized as a 72-kDa zymogen that undergoes autocatalytic cleavage in the endoplasmic reticulum into a heterodimer of a prosegment (122 amino acids) and a 60-kDa active form, which is secreted as a proteolytic inactive form (13, 14). Once secreted outside cells, PCSK9 can bind to the EGF-A extracellular domain of LDLR (15, 16) and trigger its intracellular degradation in lysosomes, thus increasing the level of circulating LDL-cholesterol (LDL-C).
###end p 3
###begin p 4
###xml 30 35 30 35 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PCSK9</italic>
###xml 129 131 129 131 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B17">17</xref>
###xml 133 135 133 135 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B18">18</xref>
###xml 167 172 167 172 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PCSK9</italic>
###xml 294 296 294 296 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B19">19</xref>
###xml 338 343 338 343 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PCSK9</italic>
###xml 443 445 443 445 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B20">20</xref>
###xml 513 518 513 518 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PCSK9</italic>
###xml 538 540 538 540 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B21">21</xref>
###xml 543 550 543 550 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">In vivo</italic>
###xml 617 622 617 622 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PCSK9</italic>
###xml 660 662 660 662 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B17">17</xref>
At the transcriptional level, PCSK9 has been identified as a target gene of sterol regulatory element binding proteins (SREBPs) (17, 18). The proximal promoter of the PCSK9 gene contains a functional sterol regulatory element (SRE) that responds to changes in intracellular cholesterol levels (19). It has been shown that insulin induces PCSK9 transcription through the interaction of SREBP1c with the SRE motif in rodent primary hepatocytes (20). In HepG2 cells both SREBP1 and SREBP2 transcriptionally activate PCSK9 via this SRE site (21). In vivo however, it was suggested that the sterol-dependent regulation of PCSK9 is mediated predominantly by SREBP2 (17).
###end p 4
###begin p 5
###xml 173 178 173 178 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PCSK9</italic>
###xml 183 187 183 187 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LDLR</italic>
###xml 321 323 321 323 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B20">20</xref>
###xml 434 436 434 436 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B13">13</xref>
###xml 438 440 438 440 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B22">22</xref>
###xml 442 444 442 444 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B23">23</xref>
###xml 494 499 494 499 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PCSK9</italic>
###xml 588 590 588 590 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B24">24</xref>
###xml 718 720 718 720 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B25">25</xref>
###xml 966 974 966 974 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
###xml 979 986 979 986 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 1038 1043 1038 1043 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PCSK9</italic>
###xml 1165 1170 1165 1170 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PCSK9</italic>
###xml 596 601 <span type="species:ncbi:9606">human</span>
Statins reduce intracellular levels of sterols and activate the SREBP pathway by inhibiting hydroxymethylglutaryl-CoA, the rate-limiting enzyme in cholesterol biosynthesis. PCSK9 and LDLR both contain an SRE motif in their proximal promoters and thus are coordinately up-regulated by statins through activation of SREBP (20). Several studies have demonstrated the induction of PCSK9 by statins in cultured cells and in animal models (13, 22, 23). The abrogation of the effect of pravastatin on PCSK9 promoter harboring a mutated SRE further confirmed its regulation by the SREBP pathway (24). In human studies, it was reported that atorvastatin at a 40-mg dose significantly elevated circulating PCSK9 protein levels (25). This led to the speculation that the diminishing efficacy of statins to further reduce LDL-C levels might be caused by the induced degradation of LDLR protein by the concomitant up-regulation of PCSK9 at higher drug doses. These findings from in vitro and in vivo studies raised an important question as to whether PCSK9 gene transcription could be separately regulated from LDLR; such a mechanism, if it existed, might be applied to inhibit PCSK9 transcription to further enhance the actions of statins to lower plasma cholesterol through their effect on LDLR transcription. This could, for example lead to a lower and more effective dose of the statins and reduce the chance of unwanted side effects.
###end p 5
###begin p 6
###xml 58 63 58 63 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PCSK9</italic>
###xml 218 220 214 216 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B24">24</xref>
###xml 471 476 467 472 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PCSK9</italic>
###xml 829 831 825 827 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B26">26</xref>
###xml 114 119 <span type="species:ncbi:9606">human</span>
Recently, several studies have reported the inhibition of PCSK9 transcription by small molecules. In immortalized human hepatocytes, activation of PPARalpha by various fibrates decreased PCSK9 mRNA and protein levels (24). Co-incubation of fenofibrate acid with statins also significantly impaired the induction of PCSK9 protein expression by pravastatin. This effect was further confirmed at the transcriptional level by showing that fenofibrate repressed the wild-type PCSK9 promoter activity alone and with pravastatin. However, this study did not further address whether SRE is the sole cis-acting element responsible for this repression. In another report, it was shown that activation of farnesoid X receptor by chenodeoxycholic acid, a bile acid, or by a farnesoid X receptor synthetic agonist repressed PCSK9 expression (26). Similar to the effects of fibrates, coadministration of chenodeoxycholic acid counteracted the statin-induced PCSK9 expression, leading to a potentiation of LDLR ligand uptake activity. The observation that chenodeoxycholic acid treatment did not change PCSK9 mRNA half-life suggested a transcriptional regulation by an unknown mechanism.
###end p 6
###begin p 7
###xml 199 201 199 201 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B27">27</xref>
###xml 201 201 201 201 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B28"/>
###xml 201 201 201 201 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B29"/>
###xml 202 204 202 204 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B30">30</xref>
###xml 347 349 347 349 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B31">31</xref>
###xml 712 717 712 717 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PCSK9</italic>
###xml 864 869 864 869 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PCSK9</italic>
Our laboratory has previously demonstrated that the natural cholesterol-lowering compound berberine (BBR) up-regulates LDLR expression through a post-transcriptional mechanism of mRNA stabilization (27-30). Interestingly, it was recently reported that BBR also exerts inhibitory effects on the expression of PCSK9 protein and mRNA in HepG2 cells (31). Thus, BBR could have dual actions on LDLR metabolism by prolonging its mRNA half-life as well as directly increasing the protein abundance through the blockage of PCSK9-mediated degradation. This would make BBR or BBR-like compounds attractive candidates for enhancing statin efficacy. Collectively, these studies provided evidence for divergent regulation of PCSK9 transcription from statins and warranted further investigations at the promoter level to fully characterize the regulatory mechanisms involved in PCSK9 transcription by BBR or other non-statin small molecules.
###end p 7
###begin p 8
###xml 24 29 24 29 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PCSK9</italic>
###xml 238 240 226 228 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B19">19</xref>
###xml 546 551 534 539 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PCSK9</italic>
###xml 573 578 561 566 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PCSK9</italic>
###xml 654 656 642 644 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B21">21</xref>
In the initial study of PCSK9 promoter, a computer-aided sequence analysis has identified putative binding sites for NF-Y (-613), Sp1 (-430), and SREBPs (-337) within a region approximately650 bp upstream from the translation start site (19). However, until this report, the SRE motif was the only proven functional cis-acting element that conferred cholesterol regulation through its interaction with SREBPs. The Sp1 binding site located 76 bp upstream of SRE was later shown to not be involved in cholesterol regulation and has a minor role in PCSK9 transcription as the PCSK9 promoter activity was moderately reduced when this Sp1 site was abolished (21).
###end p 8
###begin p 9
###xml 53 58 53 58 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PCSK9</italic>
###xml 207 212 207 212 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PCSK9</italic>
###xml 523 528 516 521 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PCSK9</italic>
In an effort to define the BBR-responsive element on PCSK9 promoter in the current study, we have identified a functional hepatocyte nuclear factor 1 (HNF1) binding site (-386 to -374) that is essential for PCSK9 transcription as a positive regulator through its interaction predominantly with HNF1alpha and to a lesser extent with HNF1beta. The HNF1 site appears to work cooperatively with the SRE as mutation of HNF1 reduced the sensitivity of the promoter to sterols and attenuated the effect of SREBP2 to transactivate PCSK9 promoter. We further showed that the HNF1 motif along with the SRE is uniquely involved in BBR-mediated transrepression of PCSK9 as mutation of either site diminished the BBR effect.
###end p 9
###begin p 10
###xml 137 139 133 135 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B32">32</xref>
###xml 139 139 135 135 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B33"/>
###xml 140 142 136 138 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B34">34</xref>
###xml 324 329 320 325 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PCSK9</italic>
###xml 302 307 <span type="species:ncbi:9606">human</span>
###xml 309 314 <span type="species:ncbi:10090">mouse</span>
###xml 320 323 <span type="species:ncbi:10116">rat</span>
Considering the fact that HNF1alpha is a liver-enriched transcription factor known to regulate many target genes in liver and intestine (32-34) and that the HNF1 site lies within the highly conserved section between Sp1 and SRE sites and its nucleotide sequence (GTTAATGTTTAAT) is 100% conserved among human, mouse, and rat PCSK9 promoters, our findings for the first time provide a mechanistic explanation for the abundant expression of PCSK9 in liver and intestine.
###end p 10
###begin title 11
EXPERIMENTAL PROCEDURES
###end title 11
###begin title 12

###end title 12
###begin title 13

###end title 13
###begin title 14
Cells and Reagents
###end title 14
###begin p 15
###xml 432 434 421 423 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B21">21</xref>
###xml 4 9 <span type="species:ncbi:9606">human</span>
###xml 161 167 <span type="species:ncbi:9913">bovine</span>
###xml 360 366 <span type="species:ncbi:9986">Rabbit</span>
The human hepatoma cell line HepG2 was obtained from American Type Culture Collection and cultured in minimum essential eagle medium supplemented with 10% fetal bovine serum (FBS). Antibodies specific to the following proteins were obtained from Santa Cruz Biotechnology: HNF1alpha (sc-6547x), HNF1beta (Sc-22840x), HNF4alpha (sc-8987x), and HDAC-1 (sc-7872). Rabbit anti-SREBP2 and anti-PCSK9 antibodies were previously described (21). Berberine chloride, lovastatin, and simvastatin were obtained from Sigma. Fluvastatin was generously provided by Novartis (Ringaskiddy, Co., Cork, Ireland).
###end p 15
###begin p 16
###xml 18 23 18 23 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PCSK9</italic>
###xml 127 129 127 129 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B21">21</xref>
###xml 268 270 254 256 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B21">21</xref>
###xml 272 274 258 260 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B35">35</xref>
###xml 276 278 262 264 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B36">36</xref>
The constructs of PCSK9 promoter luciferase reporters (D1, D4, D5, D6, SRE-mu, and Sp1-mu) were generated as described before (21). Expression vectors of nuclear SREBP2 (pTK-nBP2), HNF1alpha (pTS-HNF1alpha), and HNF1beta (pTS-HNF1beta) have been previously described (21, 35, 36). In this study, the HNF1 mutant construct (HNF1-mu) was generated from D4 using the QuikChange site-directed mutagenesis kit (Stratagene) and the following sense oligonucleotide: 5'-AGTCCGGGGGTTCCtggAATGTTTAATCAGATAGGATC-3'. The small letters are mutated nucleotides. The HNF1/SRE dual mutated construct was generated using SRE-mu as the template and the above oligonucleotide. The correct sequence was verified by DNA sequencing.
###end p 16
###begin title 17
Generation of Stable Clones Expressing a PCSK9 Promoter Luciferase Reporter
###end title 17
###begin p 18
###xml 91 96 91 96 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PCSK9</italic>
###xml 197 199 197 199 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B21">21</xref>
The plasmid pGL3-PCSK9-D1 (hereafter referred to as D1) contains 5'-flanking region of the PCSK9 gene from -1711 to -94, relative to the ATG start codon in front of the luciferase coding sequence (21). D1 and an empty vector pcDNA3.1 harboring a neomycin-resistant gene were cotransfected into HepG2 cells in a DNA ratio of 50:1 using a MicroPorator (Digital Bio, Seoul, Korea). Positive clones were selected by G418 (Invitrogen) at a concentration of 800 mug/ml. Three individual clones (CL26, CL28, and CL30) were tested for their responses to statin or BBR treatment, and clone 26 (CL26) was further used in this study.
###end p 18
###begin title 19
Transient Transfections of Reporter Constructs
###end title 19
###begin p 20
###xml 0 5 0 5 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PCSK9</italic>
###xml 99 106 99 106 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Renilla</italic>
###xml 240 242 240 242 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B21">21</xref>
###xml 299 306 299 306 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Renilla</italic>
###xml 328 330 328 330 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B21">21</xref>
PCSK9 promoter reporters of wild-type, deletion, and mutation constructs were cotransfected with a Renilla luciferase vector constitutively expressed as a transfection control, and the dual luciferase activities were measured as described (21). The firefly luciferase activity was normalized to the Renilla luciferase activity (21). In experiments of sterol regulation, transfected cells were cultured in medium containing 10% lipoprotein-depleted serum (LPDS) or LPDS plus cholesterol (10 mug/ml cholesterol plus 1 mug/ml 25-hydroxycholesterol) for 24 h prior to cell lysis for the measurement of dual luciferase activities.
###end p 20
###begin p 21
###xml 35 36 35 36 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">4</sup>
###xml 91 96 91 96 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PCSK9</italic>
###xml 548 551 <span type="species:ncbi:9685">cat</span>
###xml 704 707 <span type="species:ncbi:9685">cat</span>
To measure the BBR effect, 1.5 x 104 HepG2 cells per well were seeded into 96-well plates. PCSK9 promoter constructs were cotransfected with pSV-beta-galactosidase control vector. One day post-transfection the medium was changed to 0.5% FBS in minimum essential eagle medium overnight, and BBR was added for 24 h. Cells were lysed in 50 mul of reporter lysis buffer per well of which 20 mul of cell lysate were used to measure beta-galactosidase activity according to the manufacturer's instruction by using beta-Galactosidase Enzyme Assay System (cat. no. E2000, Promega, Madison, WI). The remaining 30 mul of lysate was used to measure the firefly luciferase activity by using Luciferase Assay System (cat. no. E1501, Promega). Absolute luciferase activity was normalized against beta-galactosidase activity to correct for transfection efficiency. Triplicate wells were assays for each transfection condition, and at least four independent transfection assays were performed for each reporter construct.
###end p 21
###begin title 22
Electrophoretic Mobility Shift Assays
###end title 22
###begin p 23
###xml 51 53 51 53 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B30">30</xref>
###xml 165 167 161 163 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">32</sup>
###xml 210 211 206 207 <sc xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">m</sc>
###xml 229 230 225 226 <sc xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">m</sc>
###xml 235 236 231 232 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 241 242 237 238 <sc xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">m</sc>
###xml 263 264 259 260 <sc xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">m</sc>
###xml 447 449 440 442 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">32</sup>
###xml 514 515 507 508 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">5</sup>
###xml 649 650 642 643 <sc xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">m</sc>
###xml 661 662 654 655 <sc xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">m</sc>
###xml 678 679 671 672 <sc xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">m</sc>
###xml 996 1000 982 986 <underline xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">GTTA</underline>
###xml 1000 1009 986 995 <underline xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ATGTTTAAT</underline>
###xml 1060 1076 1046 1062 <underline xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">GTTcgTGTTgccTCAG</underline>
HepG2 nuclear extracts were prepared as described (30). Oligonucleotide probes were annealed and end-labeled with T4 polynucleotide kinase in the presence of [gamma-32P]ATP. Each binding reaction comprised 10 mm Tris, pH 7.5, 5 mm MgCl2, 1 mm dithiothreitol, 50 mm KCl, 2.5% glycerol, 1 mug of poly(dI-dC), 0.05% Nonidet P-40, and 10 mug of HepG2 nuclear extract in a final volume of 20 mul. The nuclear extracts were incubated with 0.4-0.5 ng of 32P-labeled double-stranded synthetic oligonucleotide probe (1 x 105 cpm) for 10 min at room temperature. The reaction mixtures were loaded onto a 5% polyacrylamide gel and run in 0.5 x TBE buffer (89 mm Tris, 89 mm borate, and 2 mm EDTA, pH 8.4) at 30 mA for 2 h at 4 degreesC. Gels were dried and visualized on a PhosphorImager. For supershift assays, 2 mug of antibody was incubated with samples for 10 min at room temperature prior to the addition of the probe. The sense sequences of EMSA probes were as follows: PCSK9HNF1-UP, 5'-AGTCCGGGGGTTCCGTTAATGTTTAATCAGATAGGATC-3' and PCSK9HNF1MU-UP, 5'-GTCCGGGGGTTCCGTTcgTGTTgccTCAGATAGGATC-3'. The HNF1 binding site is underlined.
###end p 23
###begin title 24
Chromatin Immunoprecipitation
###end title 24
###begin p 25
###xml 112 113 112 113 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">7</sup>
###xml 127 129 127 129 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B33">33</xref>
###xml 1066 1071 1052 1057 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PCSK9</italic>
###xml 432 436 <span type="species:ncbi:9925">goat</span>
###xml 464 470 <span type="species:ncbi:9986">rabbit</span>
###xml 505 509 <span type="species:ncbi:9925">goat</span>
###xml 513 519 <span type="species:ncbi:9986">rabbit</span>
###xml 1060 1065 <span type="species:ncbi:9606">human</span>
The ChIP assays were conducted according to the described protocol using aliquots of lysate obtained from 2 x 107 HepG2 cells (33). Briefly, cells were fixed in 1.42% formaldehyde for 15 min at room temperature. Cells were lysed and nuclear pellet was isolated. The chromatin was sheared to an average length of 0.5-1 kb by sonicating suspended nuclear pellets. Samples were immunoprecipitated at 4 degreesC overnight with 4 mug of goat anti-HNF1alpha (sc-6547x), rabbit anti-HNF1beta (sc-22840x), normal goat or rabbit IgG as negative controls. Immunocomplexes were isolated by binding to protein A-agarose beads after extensive washing with the immunoprecipitation buffer. Chelex 100 slurry was added to the washed beads and boiled for 10 min. Precipitated DNA was isolated after ethanol precipitation. An aliquot of sheared chromatin was used in PCR reaction as a control for the amount of input DNA used in precipitations and was diluted 40x prior to PCR. The bound and the input DNA were analyzed by PCR with primers that amplify a 199-bp fragment of the human PCSK9 promoter region from -490 to -292, relative to the ATG start codon. The sequences of ChIP primers were as follows: PCSK9 ChIP primer 1-up, 5'-TCCAGCCCAGTTAGGATTTG-3'; PCSK9 ChIP primer 1-lo, 5'-CGGAAACCTTCTAGGGTGTG-3'.
###end p 25
###begin p 26
The PCR conditions were 95 degreesC for 4 min, 94 degreesC for 30 s, 55 degreesC for 30 s, 72 degreesC for 30 s, and 72 degreesC for 7 min. The 199-bp PCR product was visualized on a 2% agarose gel stained with ethidium bromide. The intensity of the PCR products was scanned and quantified with Kodak Image Station 4000R System.
###end p 26
###begin title 27
siRNA Transfection
###end title 27
###begin p 28
###xml 395 397 388 390 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TM</sup>
###xml 530 531 523 524 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">4</sup>
###xml 688 689 680 681 <sc xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">m</sc>
###xml 38 43 <span type="species:ncbi:9606">human</span>
###xml 60 63 <span type="species:ncbi:9685">cat</span>
###xml 132 135 <span type="species:ncbi:9685">cat</span>
###xml 208 211 <span type="species:ncbi:9685">cat</span>
Three pre-designed siRNAs targeted to human HNF1alpha mRNA (cat. no. 16708A; ID 3544, 3450, and 3354), two siRNAs to HNF1beta mRNA (cat. no. 16708; ID 3262 and 3170), and one silencer negative control siRNA (cat. no. 4618G) were obtained from Ambion. Pooled siRNAs for each gene were used in this study. For promoter analysis, HepG2 CL26 cells in suspension were mixed with siRNA in the SilencerTM siRNA transfection reagent for 30 min according to the vendor's instruction and were plated in 96-well plates at a density of 1 x 104 cells/well. Twenty-four hours later, cells were cultured in minimum essential eagle medium containing 0.5% FBS overnight and BBR at a concentration of 40 mum was added for 24 h before cell lysis for measuring luciferase activity.
###end p 28
###begin p 29
###xml 55 56 55 56 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">6</sup>
###xml 100 102 100 102 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TM</sup>
For Western blotting or real-time PCR, suspended 1 x 106 cells were mixed with siRNA in the SilencerTM siRNA transfection reagent for 30 min and plated in 6-well plates. After 2 days, transfected cells were cultured in minimum essential eagle medium containing 0.5% FBS overnight and then treated with BBR for 24 h prior to cell lysis.
###end p 29
###begin title 30
RNA Isolation and Real-time Reverse Transcription-PCR
###end title 30
###begin p 31
###xml 56 58 56 58 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TM</sup>
###xml 397 402 <span type="species:ncbi:9606">Human</span>
Total RNA was extracted from HepG2 cells using UltraspecTM total RNA isolation reagent (Biotecx Laboratories). Two micrograms of total RNA was reverse transcribed with a high capacity cDNA reverse transcription kit (Applied Biosystems) using random primers according to the manufacturer's instructions. Real-time PCR was performed on the cDNA using an ABI Prism 7900-HT Sequence Detection System. Human LDLR, PCSK9, and GAPDH Pre-Developed TaqMan Assay Reagents (Applied Biosystems) were used to assess mRNA expression in HepG2 cells with or without BBR treatment. All values are reported as means +/- S.D. of triple measurement of each cDNA sample.
###end p 31
###begin title 32
Western Blot Analysis
###end title 32
###begin p 33
###xml 139 141 139 141 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B29">29</xref>
Western blot analysis was performed to examine the protein expression in untransfected or siRNA-transfected cells as previously described (29).
###end p 33
###begin title 34
Statistical Analysis
###end title 34
###begin p 35
###xml 371 372 371 372 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">t</italic>
###xml 389 390 389 390 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
Each experiment is representative of at least three independent experiments with a minimum of triplicates per condition in promoter analysis. Significant differences between control and treatment groups or between wild-type and mutated vectors were assessed by one-way analysis of variance with post test of Bonferroni multiple comparison test or by two-tailed Student's t test. Values of p < 0.05 were considered statistically significant.
###end p 35
###begin title 36
RESULTS
###end title 36
###begin title 37

###end title 37
###begin title 38

###end title 38
###begin title 39
BBR Counteracts the Inducing Effects of Statins on PCSK9 Transcription
###end title 39
###begin p 40
###xml 149 150 148 149 <sc xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">m</sc>
###xml 252 253 239 240 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 422 423 409 410 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 543 549 530 536 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F1">Fig. 1</xref>
###xml 549 550 536 537 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">A</italic>
###xml 642 643 628 629 <sc xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">m</sc>
###xml 933 939 919 925 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F1">Fig. 1</xref>
###xml 939 940 925 926 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">B</italic>
###xml 1066 1068 1052 1054 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B31">31</xref>
The time-dependent effects of BBR on the mRNA expression of LDLR and PCSK9 were examined in HepG2 cells that were treated with BBR at a dose of 20 mum for various times. BBR increased LDLR mRNA by approximately1.8-fold at 4 h and up to 3-fold at 24 h (p < 0.001), and this elevation was observed for at least 48 h. Conversely, the amount of PCSK9 mRNA was decreased by BBR treatment. A 30% reduction was detected at 12 h (p < 0.01), and the mRNA level of PCSK9 gradually declined in BBR-treated cells down to 23% of untreated control by 48 h (Fig. 1A). To further evaluate the effect of BBR on PCSK9 mRNA expression we treated cells with 1 mum of fluvastatin, lovastatin, or simvastatin in the absence or presence of two different concentrations of BBR. Although statins individually increased PCSK9 mRNA levels above 2-fold of control, their inducing effects were not observed in cells concomitantly treated with BBR at both doses (Fig. 1B). These results are in line with a previous observation of counteraction of BBR on mevastatin-induced PCSK9 mRNA expression (31).
###end p 40
###begin p 41
###xml 37 42 37 42 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PCSK9</italic>
###xml 0 81 0 81 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Berberine transcriptionally inhibits <italic>PCSK9</italic> while upregulating LDLR mRNA quantity.</bold>
###xml 81 82 81 82 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">A</italic>
###xml 143 144 142 143 <sc xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">m</sc>
###xml 363 364 362 363 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 381 382 380 381 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 443 444 442 443 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 499 500 498 499 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">B</italic>
###xml 593 594 591 592 <sc xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">m</sc>
###xml 611 616 609 614 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Fluva</italic>
###xml 631 635 629 633 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Lova</italic>
###xml 654 659 652 657 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Simva</italic>
###xml 733 734 731 732 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 751 752 749 750 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 787 788 785 786 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">C</italic>
###xml 861 862 859 860 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">D</italic>
###xml 905 906 902 903 <sc xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">m</sc>
###xml 926 927 922 923 <sc xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">m</sc>
###xml 1189 1190 1185 1186 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 1207 1208 1203 1204 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 1267 1268 1263 1264 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">A</italic>
###xml 1270 1271 1266 1267 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">B</italic>
###xml 1277 1278 1273 1274 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">D</italic>
###xml 1372 1373 1366 1367 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">C</italic>
Berberine transcriptionally inhibits PCSK9 while upregulating LDLR mRNA quantity.A, HepG2 cells were exposed to BBR at a concentration of 20 mum for various times. PCSK9, LDLR, and glyceraldehyde-3-phosphate dehydrogenase mRNA levels were quantified by real-time PCR, and mRNA relative levels are presented. Triplicate RNA samples were measured per condition. *, p < 0.05 and ***, p < 0.001 as compared with time 0 h of PCSK9 mRNA level; ###, p < 0.001 as compared with time 0 h of LDLR mRNA level. B, HepG2 cells were treated with indicated doses of BBR in the absence or the presence of 1 mum of fluvastatin (Fluva), lovastatin (Lova), or simvastatin (Simva) for 24 h, and the PCSK9 mRNA abundance was assayed by real-time PCR. *, p < 0.05 and ***, p < 0.001 as compared with control. C, CL26 cells were incubated with BBR at various concentrations for 24 h. D, CL26 cells were incubated with BBR (40 mum) alone or with 1 mum of each statin for 24 h. Luciferase activities are expressed in relative to untreated control cells. Significant differences between control and treatment groups were assessed by one-way analysis of variance with post test of Bonferroni multiple comparison. *, p < 0.05 and ***, p < 0.001 as compared with untreated control. Data shown in A, B, and D are representative of two separate experiments with similar results. Data (mean +/- S.D.) in C are derived from four separate assays.
###end p 41
###begin p 42
###xml 165 171 165 171 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F2">Fig. 2</xref>
###xml 171 172 171 172 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">A</italic>
###xml 174 176 174 176 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">D1</italic>
###xml 222 227 222 227 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PCSK9</italic>
###xml 285 287 285 287 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B21">21</xref>
###xml 485 490 485 490 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PCSK9</italic>
###xml 606 611 606 611 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PCSK9</italic>
###xml 631 637 631 637 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F1">Fig. 1</xref>
###xml 637 638 637 638 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">C</italic>
###xml 703 708 703 708 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PCSK9</italic>
###xml 729 735 729 735 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F1">Fig. 1</xref>
###xml 735 736 735 736 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">D</italic>
###xml 839 840 838 839 <sc xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">m</sc>
###xml 1077 1082 1076 1081 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PCSK9</italic>
To firmly demonstrate the transcriptional inhibition of PCSK9 mRNA expression by BBR, we established stable clones of HepG2 cells expressing a luciferase construct (Fig. 2A, D1) that contains the 5'-flanking region of the PCSK9 gene from -1711 to -94, relative to the ATG start codon (21). Preliminary screens of clones (CL26, CL28, and CL30) showed that luciferase activities of these clones were increased by simvastatin and were reduced by BBR, mimicking the response of endogenous PCSK9 transcriptional activity to the drug treatments. CL26 cells were studied to show a dose-dependent effect of BBR on PCSK9 promoter activity (Fig. 1C) and to demonstrate the antagonism of BBR on the statin-induced PCSK9 promoter construct (Fig. 1D). In parallel, we conducted a cell proliferation assay and demonstrated that BBR at a high dose (40 mum) did not affect cell growth under the assay conditions, indicating that the decreased luciferase activity in BBR-treated cells was not caused by reduction of viable cell number. Taken together, these results establish that BBR inhibits PCSK9 gene expression by suppressing its promoter transcriptional activity.
###end p 42
###begin p 43
###xml 12 17 12 17 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PCSK9</italic>
###xml 0 108 0 108 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Analysis of <italic>PCSK9</italic> promoter constructs in transiently transfected HepG2 cells without and with BBR treatment.</bold>
###xml 108 109 108 109 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">A</italic>
###xml 183 188 183 188 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PCSK9</italic>
###xml 294 295 294 295 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">B</italic>
###xml 781 782 775 776 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">C</italic>
###xml 945 946 937 938 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 978 979 970 971 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">B</italic>
###xml 1018 1019 1010 1011 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">C</italic>
###xml 177 182 <span type="species:ncbi:9606">human</span>
Analysis of PCSK9 promoter constructs in transiently transfected HepG2 cells without and with BBR treatment.A, schematic presentation of the deletion and mutation constructs of human PCSK9 promoter-luciferase reporters. Position -1 was assigned to the nucleotide preceding the ATG start codon. B, the reporter constructs were transiently cotransfected with pSV-beta-gal vector into HepG2 cells. One day post transfection, cells were incubated in 0.5% FBS medium overnight, followed by a 24-treatment of BBR. Cells were harvested, and the luciferase and beta-galactosidase activities were measured as described under "Experimental Procedures." After normalization, the relative luciferase unit of each vector is expressed as the percent of the luciferase activity of the D4 vector. C, relative luciferase activity of transfected cells that were untreated is expressed as 100%. Results shown are mean +/- S.D. of four separate transfections. ***, p < 0.001 as compared with D4 in B or compared with untreated control in C.
###end p 43
###begin title 44
Characterization of the PCSK9 Promoter to Define BBR-responsive Sequences
###end title 44
###begin p 45
###xml 26 31 26 31 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PCSK9</italic>
###xml 96 101 96 101 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PCSK9</italic>
###xml 123 129 123 129 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F2">Fig. 2</xref>
###xml 129 130 129 130 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">A</italic>
###xml 417 423 414 420 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F2">Fig. 2</xref>
###xml 425 426 422 423 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">B</italic>
###xml 431 432 428 429 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">C</italic>
###xml 435 441 432 438 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F2">Fig. 2</xref>
###xml 441 442 438 439 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">B</italic>
###xml 536 542 533 539 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F2">Fig. 2</xref>
###xml 542 543 539 540 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">C</italic>
To define which region of PCSK9 promoter is responsive to BBR treatment we transfected a set of PCSK9 promoter constructs (Fig. 2A) into HepG2 cells together with plasmid pSV-beta-gal for normalization. In these experiments, we included the promoter-less vector pGL3-basic as a negative control whose luciferase activity was not affected by BBR. The summarized results of four separate transfections are presented in Fig. 2 (B and C). Fig. 2B shows the basal luciferase activity of each construct, relative to the wild-type plasmid D4. Fig. 2C compares the inhibitory effect of BBR on different promoter constructs.
###end p 45
###begin p 46
###xml 44 49 44 49 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PCSK9</italic>
###xml 579 581 567 569 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B21">21</xref>
###xml 646 651 634 639 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PCSK9</italic>
###xml 973 978 961 966 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PCSK9</italic>
###xml 1075 1080 1063 1068 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PCSK9</italic>
Plasmid D4 contains the functional proximal PCSK9 promoter (-440 to -94) wherein the Sp1 and SRE sites reside. BBR reduced D4 activity by 64%. Mutation of the Sp1 site modestly lowered the basal promoter activity to approximately63% of the wild type but had no effect on the BBR response. SRE mutation reduced the basal promoter activity by 86% and also partially prevented the BBR-mediated inhibition. Deletion of a small segment of 48 bp covering the Sp1 site from the 5' proximal region of D4 slightly increased the basal activity of D5 (consistent with the previous report) (21), and the BBR response was fully retained in D5. Interestingly, PCSK9 promoter activity was drastically reduced by a further deletion of 41 bp from -392 to -352, and the resulting plasmid D6 became resistant to BBR treatment despite the presence of an intact SRE. These results suggest that, although the SRE motif is partially involved in the BBR-mediated suppression, the small segment of PCSK9 promoter upstream of SRE might contain a cis-regulatory element that is critically required for PCSK9 gene transcription and is likely involved in the action of BBR.
###end p 46
###begin title 47
Identification of HNF1 Binding Site as an Essential Regulatory Element for PCSK9 Transcription
###end title 47
###begin p 48
###xml 61 66 61 66 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PCSK9</italic>
###xml 329 334 329 334 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PCSK9</italic>
###xml 346 352 346 352 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F3">Fig. 3</xref>
###xml 352 353 352 353 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">A</italic>
###xml 566 572 566 572 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F3">Fig. 3</xref>
###xml 572 573 572 573 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">B</italic>
###xml 674 679 674 679 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PCSK9</italic>
###xml 735 741 723 729 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F3">Fig. 3</xref>
###xml 741 742 729 730 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">B</italic>
###xml 863 868 851 856 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PCSK9</italic>
###xml 1165 1166 1153 1154 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 1236 1237 1224 1225 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 1248 1254 1236 1242 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F3">Fig. 3</xref>
###xml 1254 1255 1242 1243 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">C</italic>
###xml 1439 1444 1427 1432 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PCSK9</italic>
###xml 1534 1539 1522 1527 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PCSK9</italic>
###xml 307 312 <span type="species:ncbi:9606">human</span>
###xml 314 319 <span type="species:ncbi:10090">mouse</span>
###xml 325 328 <span type="species:ncbi:10116">rat</span>
Analysis of nucleotide sequence within this 41-bp segment of PCSK9 promoter by the MatInspector software revealed the presence of a strong HNF1 binding site spanning the region -386 to -374. This HNF1 site resides 28 bp upstream from the SRE and 35 bp downstream of the Sp1 site. It is 100% conserved among human, mouse, and rat PCSK9 promoters (Fig. 3A). We mutated the core nucleotide sequence of the HNF1 site and transfected the mutated plasmid along with the wild type, SRE-mu, Sp1-mu, and the pGL3-basic vector individually into HepG2 cells. The data shown in Fig. 3B were derived from eight separate transfection experiments. Destroying the HNF1 binding site reduced PCSK9 promoter activity to approximately5% of the wild type (Fig. 3B), even more severe than SRE mutation (13.8% of the wild type), indicating that it is a vital cis-regulatory element for PCSK9 gene transcription. The combined mutation of HNF1 and SRE resulted in a complete loss of the promoter activity (data not shown). Although BBR-mediated suppression of luciferase activity was not affected by Sp1 mutation, mutation of SRE reduced BBR inhibitory activity from 35% to 62% of control (p < 0.01) and HNF1 mutation attenuated BBR activity to 73% of control (p < 0.001) (Fig. 3C). In contrast to the PCSK9 reporters, the negative control vector, pGL3-basic showed no response to BBR. Taken together, these data demonstrated the critical roles of HNF1 and SRE in PCSK9 transcription and their involvement in mediating the effect of BBR on transrepression of PCSK9.
###end p 48
###begin p 49
###xml 34 39 34 39 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PCSK9</italic>
###xml 0 83 0 83 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HNF1 binding site is critical for <italic>PCSK9</italic> transcription and BBR-mediated suppression.</bold>
###xml 83 84 83 84 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">A</italic>
###xml 129 134 129 134 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PCSK9</italic>
###xml 170 194 170 194 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Gray-highlighted letters</italic>
###xml 262 263 262 263 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">B</italic>
###xml 268 269 268 269 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">C</italic>
###xml 373 379 371 377 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F2">Fig. 2</xref>
###xml 384 385 382 383 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">B</italic>
###xml 515 516 513 514 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">C</italic>
###xml 626 627 624 625 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 641 642 639 640 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 147 152 <span type="species:ncbi:9606">human</span>
###xml 154 159 <span type="species:ncbi:10090">mouse</span>
###xml 165 168 <span type="species:ncbi:10116">rat</span>
HNF1 binding site is critical for PCSK9 transcription and BBR-mediated suppression.A, sequence comparison of proximal regions of PCSK9 promoter of human, mouse, and rat. Gray-highlighted letters indicate divergent nucleotides among the three promoter sequences. B and C, summarized results (means +/- S.D.) of eight independent transfections and treatments as described in Fig. 2. In B, the normalized basal luciferase activity of each vector is expressed as the percent of luciferase activity of the D4 vector. In C, the response of each mutant vector to BBR inhibition was compared with that of the wild-type D4 vector. **, p < 0.01; ***, p < 0.001.
###end p 49
###begin p 50
###xml 109 111 109 111 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B37">37</xref>
###xml 111 111 111 111 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B38"/>
###xml 112 114 112 114 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B39">39</xref>
###xml 135 140 135 140 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PCSK9</italic>
###xml 458 464 458 464 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F4">Fig. 4</xref>
###xml 464 465 464 465 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">A</italic>
###xml 509 514 509 514 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PCSK9</italic>
###xml 935 940 935 940 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PCSK9</italic>
In typical promoters of cholesterol biosynthetic genes SRE motifs are adjacent to Sp1 or NF-Y binding sites (37-39). To our knowledge, PCSK9 is the first identified gene, involving in cellular cholesterol metabolism that utilizes an HNF1 binding site to cooperate with SRE. To determine whether the HNF1 motif is involved in cholesterol regulation, we tested promoter activities of various constructs in cells cultured in the absence or presence of sterols. Fig. 4A shows that the transcriptional activity of PCSK9 promoter was decreased by 83 and 88% in the presence of sterols in wild-type constructs D4 and D5. Mutation of Sp1 did not diminish the sterol effect at all (88% repression). In contrast, mutation of SRE as well as the HNF1 site in the D4 construct nearly abolished the sterol-dependent suppression of transcription. These results clearly demonstrate that Sp1 has no functional role in the sterol-mediated regulation of PCSK9 transcription but HNF1 site is critically involved.
###end p 50
###begin p 51
###xml 123 128 123 128 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PCSK9</italic>
###xml 0 138 0 138 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Examination of responses of the wild-type and mutated vectors to sterol suppression and SREBP2-mediated transactivation of <italic>PCSK9</italic> promoter.</bold>
###xml 138 139 138 139 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">A</italic>
###xml 187 194 187 194 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Renilla</italic>
###xml 628 639 626 637 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">upper panel</italic>
###xml 649 660 647 658 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">lower panel</italic>
###xml 664 665 662 663 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">A</italic>
###xml 875 880 873 878 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">value</italic>
###xml 1000 1001 996 997 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 1011 1012 1007 1008 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">B</italic>
###xml 1268 1269 1263 1264 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">A</italic>
###xml 1276 1281 1271 1276 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">value</italic>
###xml 1344 1345 1337 1338 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 218 222 <span type="species:ncbi:10633?0.9966199903428296">SV40</span>
Examination of responses of the wild-type and mutated vectors to sterol suppression and SREBP2-mediated transactivation of PCSK9 promoter.A, reporter constructs were cotransfected with a Renilla expression vector (pRL-SV40) into HepG2 cells. One day post transfection, cells were cultured in medium supplemented with 10% LPDS or LPDS plus cholesterol (10 mug/ml cholesterol plus 1 mug/ml 25-hydroxycholesterol) for 24 h prior to cell lysis to measure dual luciferase activities. After normalization, the luciferase activity of each vector is expressed as the percent of the luciferase activity of the D4 vector without sterols (upper panel). In the lower panel of A, the luciferase activity of each vector in the absence of sterols is expressed as 100%. The relative luciferase of each vector in the presence of sterols was compared with that in the absence of sterols. Each value represents the mean +/- S.D. of four independent transfection experiments in which triplicate wells were assayed. ***, p < 0.001. B, HepG2 cells were cotransfected with indicated PCSK9 luciferase reporters with different amounts of pTK-nBP2. Total amounts of transfected plasmids were adjusted to 0.2 mug/well with a mock vector. Dual Luciferase activities were measured as described in A. Each value represents the mean +/- S.D. of six wells per condition. ***, p < 0.001 as compared with 0 ng/well pTK-nBP2. The data shown are representative of three separate transfections with similar results.
###end p 51
###begin p 52
###xml 117 122 117 122 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PCSK9</italic>
###xml 365 371 365 371 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F4">Fig. 4</xref>
###xml 371 372 371 372 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">B</italic>
###xml 485 490 485 490 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PCSK9</italic>
###xml 616 622 616 622 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F4">Fig. 4</xref>
###xml 622 623 622 623 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">B</italic>
###xml 738 743 738 743 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PCSK9</italic>
To further examine the relationship between SRE and HNF1 motifs, we examined the SREBP2-mediated trans-activation of PCSK9 promoters, including the wild-type, SRE-mutated, HNF1-mutated, and Sp1-mutated plasmids. Individual reporter constructs were cotransfected into HepG2 cells with a plasmid expressing the nuclear form of SREBP2 (pTK-nBP2) at different amounts. Fig. 4B shows that expressions of nSREBP2 dose-dependently increased the transcription of the wild-type and Sp1 mutated PCSK9 promoter activities. In contrast, the promoter activities of SRE-mu and HNF-mu were not significantly stimulated by nSREBP2 (Fig. 4B). These data further support the model that SREBP2 and HNF1 binding proteins may work cooperatively in control of PCSK9 gene transcription.
###end p 52
###begin title 53
HNF1alpha Has a Predominant Role in PCSK9 Transcription
###end title 53
###begin p 54
###xml 62 67 62 67 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PCSK9</italic>
###xml 112 114 112 114 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">32</sup>
###xml 170 175 170 175 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PCSK9</italic>
###xml 271 277 271 277 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F5">Fig. 5</xref>
###xml 277 278 277 278 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">A</italic>
To detect transcription factors that bind to the HNF1 site of PCSK9 promoter, gel mobility shift assays using a 32P-labeled oligonucleotide probe (PCSK9-HNF1) containing PCSK9 promoter sequence -400 to -362 were performed with nuclear extracts prepared from HepG2 cells (Fig. 5A). Two complexes (C1 and C2) were detected with C1 being the abundant one. Formation of both complexes was inhibited by a 100-fold molar excess of the unlabeled wild-type oligonucleotides, but was not inhibited by a 100-fold molar excess of oligonucleotides containing the mutated HNF1 sequence, demonstrating the binding specificity. Moreover, the complexes were completely supershifted by anti-HNF1alpha antibody, whereas an irrelevant antibody anti- HNF4alpha had no effect on the mobility of the complexes. Anti-HNF1beta antibody produced a supershifted band of a much lower intensity compared with anti-HNF1alpha antibody. These results suggest that PCSK9-HNF1 site predominantly interacts with HNF1alpha and to a lesser extend with HNF1beta, likely through homodimerization of HNF1alpha and heterodimerization of 1alpha and 1beta in the cellular context of HepG2.
###end p 54
###begin p 55
###xml 70 75 63 68 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PCSK9</italic>
###xml 0 100 0 93 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EMSA and ChIP analyses of HNF1&#945; and HNF1&#946; association with the <italic>PCSK9</italic> promoter in HepG2 cells.</bold>
###xml 100 101 93 94 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">A</italic>
###xml 181 186 174 179 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PCSK9</italic>
###xml 285 294 277 286 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">lanes 2&#8211;7</italic>
###xml 338 344 324 330 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">lane 2</italic>
###xml 408 414 394 400 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">lane 3</italic>
###xml 433 439 419 425 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">lane 4</italic>
###xml 541 547 522 528 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">lane 5</italic>
###xml 571 577 549 555 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">lane 6</italic>
###xml 652 658 626 632 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">lane 7</italic>
###xml 661 662 635 636 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">B</italic>
###xml 810 815 777 782 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PCSK9</italic>
###xml 1103 1108 1070 1075 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Input</italic>
###xml 876 882 <span type="species:ncbi:9986">rabbit</span>
###xml 891 895 <span type="species:ncbi:9925">goat</span>
EMSA and ChIP analyses of HNF1alpha and HNF1beta association with the PCSK9 promoter in HepG2 cells.A, a double-stranded oligonucleotide (designated as PCSK9-HNF1) corresponding to PCSK9 promoter region -400 to -362 was radiolabeled and incubated with 10 mug of HepG2 nuclear extract (lanes 2-7) for 10 min at 22 degreesC in the absence (lane 2) or presence of 100-fold molar amounts of unlabeled wild-type (lane 3) or mutated HNF1 (lane 4) probes. The binding reactions were also carried out in the presence of 2 mug of HNF1alpha antibody (lane 5) or HNF1beta antibody (lane 6). Anti-HNF4alpha antibody was included as an irrelevant negative control (lane 7). B, antibodies to HNF1alpha and HNF1beta were used in a ChIP analysis followed by PCR to amplify a 199-bp region surrounding the HNF1 binding site of PCSK9 promoter from genomic DNA isolated from HepG2 cells. Normal rabbit IgG and goat IgG were included in the assay as negative controls for nonspecific binding. The PCR product was separately on a 2% agarose gel, stained with ethidium bromide, and quantified by a Kodak Image Station 4000R. Input represents the starting material before immunoprecipitation. The data shown are representative of two separate EMSA and ChIP assays with similar results.
###end p 55
###begin p 56
###xml 15 22 15 22 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 57 62 57 62 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PCSK9</italic>
###xml 155 160 148 153 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PCSK9</italic>
###xml 207 213 200 206 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F5">Fig. 5</xref>
###xml 213 214 206 207 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">B</italic>
###xml 437 445 411 419 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
To examine the in vivo interactions of HNF1 factors with PCSK9 promoter, we performed ChIP assays to detect the direct binding of HNF1alpha or HNF1beta to PCSK9 promoter HNF1 sequence in intact HepG2 cells. Fig. 5B shows that, although both isoforms of HNF1 were cross-linked to the HNF1 motif, the level of HNF1alpha bound to the HNF1 motif was approximately2.5-fold higher than HNF1beta. Thus, the results of ChIP strongly support our in vitro finding that HNF1alpha is the major isoform of HNF1 factors that recognizes PCSK9-HNF1 sequence motif in HepG2 cells.
###end p 56
###begin p 57
###xml 53 58 53 58 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PCSK9</italic>
###xml 175 180 168 173 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PCSK9</italic>
###xml 524 529 510 515 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PCSK9</italic>
To determine the functional role of HNF1 isoforms in PCSK9 transcription, we first transfected siRNAs targeted to HNF1alpha or HNF1beta into HepG2-CL26 cells that express the PCSK9 promoter construct D1. A nonspecific siRNA with scrambled nucleotide sequence was included in the experiments as a negative control. Compared with the nonspecific siRNA, transfections of siHNF1alpha and siHNF1beta lowered luciferase activity by 94 and 63%, respectively. Depletion of HNF1 factors also compromised the BBR inhibitory effect on PCSK9 promoter.
###end p 57
###begin p 58
###xml 376 382 369 375 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F6">Fig. 6</xref>
###xml 382 383 375 376 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">B</italic>
Next, we examined the effects of siRNA transfection on the expression of endogenous PCSK9 mRNA in HepG2 cells with or without BBR treatment by real-time PCR. Consistent with the data of promoter analysis, the level of PCSK9 mRNA was drastically decreased to 15% of control in siHNF1alpha-transfected cells, and the effect of siHNF1beta was again less severe (56% of control) (Fig. 6B).
###end p 58
###begin p 59
###xml 51 56 44 49 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PCSK9</italic>
###xml 0 140 0 133 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Effects of siHNF1&#945; and siHNF1&#946; knockdown on <italic>PCSK9</italic> transcription and protein expression in HepG2 cells untreated and treated with BBR.</bold>
###xml 140 141 133 134 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">A</italic>
###xml 155 160 148 153 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PCSK9</italic>
###xml 310 311 302 303 <sc xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">m</sc>
###xml 467 468 457 458 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">B</italic>
###xml 709 710 697 698 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">C</italic>
###xml 1110 1111 1098 1099 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">D</italic>
###xml 1469 1470 1443 1444 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">E</italic>
###xml 1579 1581 1553 1555 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">32</sup>
###xml 1630 1631 1604 1605 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">F</italic>
###xml 1673 1674 1646 1647 <sc xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">m</sc>
###xml 1946 1949 1914 1917 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">C&#8211;F</italic>
###xml 804 808 <span type="species:ncbi:10633?0.9966199903428296">SV40</span>
Effects of siHNF1alpha and siHNF1beta knockdown on PCSK9 transcription and protein expression in HepG2 cells untreated and treated with BBR.A, analysis of PCSK9 promoter activity in CL26 cells transfected with targeted siRNA or control nonspecific siRNA. Cells were treated with BBR at a concentration of 40 mum or its vehicle (0.1% DMSO) as control for 24 h prior to cell lysis. Data represent the means +/- S.D. derived from four separate transfection experiments. B, real-time reverse transcription-PCR analysis of PCSK9 mRNA levels in HepG2 cells after siRNA transfection of 2 days followed by BBR treatment of 24 h. Data represent the means +/- S.E. derived from three separate transfection experiments. C, D4 was cotransfected with either pTS-HNF1a, pTS-HNF1b, or with a mock vector along with pRL-SV40 in a DNA ratio of 2:1:0.2 into HepG2 cells. Dual luciferase activities were measured. The normalized luciferase activity in D4-transfected cells with the mock vector is expressed as 100%, and luciferase activities in cells transfected with other expression vectors are plotted relative to that value. D, Western blot analysis of HNF1alpha, PCSK9, and beta-actin in total cell lysates of siRNA-transfected HepG2 cells without and with BBR treatment. The HNF1alpha and PCSK9 bands were quantified using an imaging program of Kodak Image Station 4000R. Values were normalized to beta-actin and were graphed relative to untreated cells without siRNA transfection. E, indicated amounts of nuclear extracts prepared from untreated or BBR-treated cells were incubated with the 32P-labeled PCSK9-HNF1 probe and analyzed by EMSA. F, HepG2 cells were treated with BBR (40 mum) or its vehicle 0.1% DMSO as control for 24 h. Nuclear extracts were isolated. 50 mug of nuclear proteins from each sample was analyzed by Western blotting with HNF1alpha antibody, followed by blotting the membrane with anti-HDAC1 as a loading control. The data shown in C-F are representative of 2-3 separate experiments with similar results.
###end p 59
###begin p 60
###xml 90 95 83 88 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PCSK9</italic>
###xml 289 294 275 280 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PCSK9</italic>
###xml 388 394 367 373 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F6">Fig. 6</xref>
###xml 394 395 373 374 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">C</italic>
###xml 468 473 443 448 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PCSK9</italic>
In addition to knockdown, effects of exogenous overexpression of HNF1alpha or HNF1beta on PCSK9 transcription were studied. Plasmid D4 was cotransfected with pTS-HNF1alpha, pTS-HNF1beta, or the mock vector into HepG2 cells, and the luciferase activity was measured 48 h post transfection. PCSK9 promoter activity was increased 158 and 41% by pTS-HNF1alpha and pTS-HNF1beta, respectively (Fig. 6C). All together, these data point to HNF1alpha as the critical factor in PCSK9 transcription, which is in line with the findings of EMSA and ChIP showing the predominant binding of HNF1alpha to the PCSK9-HNF1 site.
###end p 60
###begin p 61
###xml 222 228 218 224 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F6">Fig. 6</xref>
###xml 228 229 224 225 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">D</italic>
###xml 329 335 317 323 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">lane 1</italic>
###xml 341 347 329 335 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">lane 3</italic>
To further confirm the primary activator role of HNF1alpha in PCSK9 expression and its involvement in BBR action, we examined PCSK9 protein expression in control and BBR-treated cells without and with siRNA transfections (Fig. 6D). The abundance of HNF1alpha protein was greatly reduced in siHNF1alpha-transfected cells (compare lane 1 with lane 3), concomitant with an extensive reduction of PCSK9 protein expression. Depletion of HNF1beta only slightly lowered PCSK9 signal.
###end p 61
###begin p 62
###xml 389 395 369 375 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F6">Fig. 6</xref>
###xml 395 396 375 376 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">E</italic>
###xml 448 450 428 430 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">32</sup>
###xml 602 608 582 588 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F6">Fig. 6</xref>
###xml 608 609 588 589 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">F</italic>
###xml 853 858 833 838 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PCSK9</italic>
Importantly, the results of Western blotting with anti-HNF1alpha further revealed that the amount of HNF1alpha protein in BBR-treated cells was decreased to approximately40% of control. This effect was also observed in siRNA-transfected cells. To validate this finding at the promoter level, we performed EMSA with nuclear extracts prepared from control and BBR-treated cells. As shown in Fig. 6E, the signal intensity of the complexes formed with 32P-labeled PCSK9-HNF1 probe was clearly reduced by BBR treatment at all three different doses. Further analysis of nuclear extracts by Western blotting (Fig. 6F) showed an equal abundance of the nuclear protein HDAC1 (histone deacetylase 1) in control and BBR-treated extracts, thereby validating the HNF1 EMSA result. These findings, combined with the promoter analysis, demonstrate that BBR suppresses PCSK9 transcription partially though its inhibitory effect on HNF1alpha expression.
###end p 62
###begin title 63
Reduction of the Nuclear Form of SREBP2 by BBR Treatment
###end title 63
###begin p 64
###xml 84 89 84 89 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PCSK9</italic>
###xml 243 249 243 249 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F7">Fig. 7</xref>
###xml 475 477 475 477 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B21">21</xref>
###xml 851 857 851 857 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F6">Fig. 6</xref>
###xml 1047 1052 1043 1048 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PCSK9</italic>
Finally, we sought to understand how SRE is involved in BBR-mediated suppression of PCSK9 transcription. We examined the expression of the nuclear and precursor forms of SREBP2 in HepG2 cells without and with treatments of BBR or simvastatin (Fig. 7). The results of Western blotting using anti-SREBP2 antibody showed that simvastatin increased the nuclear form of SREBP2 while reducing the membrane-bound precursor, a typical effect of statins on SREBP2 protein expression (21). BBR treatment resulted in a moderate reduction of nuclear SREBP2 and a lesser reduction of the precursor protein in a dose-dependent manner. The reduction of SREBP2 by BBR was accompanied by a more extensive inhibition of PCSK9 protein expression, which was in clear contrast to simvastatin that increased both nSREBP2 and PCSK9. These results, combined with the data in Fig. 6, showing a reduced expression of HNF1alpha in BBR-treated cells, suggest that BBR exerts an integrated action on these two transcription factors, which translates into a strong suppression PCSK9 transcription synergistically.
###end p 64
###begin p 65
###xml 0 99 0 99 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Reduction of SREBP2 protein by BBR treatment is partially responsible for reduced PCSK9 expression.</bold>
###xml 99 100 99 100 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">A</italic>
###xml 178 179 177 178 <sc xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">m</sc>
###xml 259 260 258 259 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">B</italic>
###xml 308 316 307 315 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SREBP2-P</italic>
###xml 335 343 334 342 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SREBP2-N</italic>
###xml 363 370 362 369 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PCSK9-P</italic>
###xml 391 398 390 397 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PCSK9-M</italic>
Reduction of SREBP2 protein by BBR treatment is partially responsible for reduced PCSK9 expression.A, HepG2 cells were treated with BBR for 24 h at concentrations of 20 and 40 mum. Total cell lysate was isolated for Western blot analysis of SREBP2 and PCSK9. B, intensities of the bands of precursor SREBP2 (SREBP2-P), nuclear SREBP2 (SREBP2-N), precursor PCSK9 (PCSK9-P), and mature PCSK9 (PCSK9-M) were quantified using an imaging program of Kodak Imaging Station 4000R. Values were normalized to beta-actin and were graphed relative to untreated cells. The figure shown is representative of three separate experiments with similar results.
###end p 65
###begin title 66
DISCUSSION
###end title 66
###begin p 67
###xml 332 337 332 337 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PCSK9</italic>
We set out to understand the interesting conundrum of the differential action of the plant-derived hypocholesterolemic compound berberine on a gene shown to be important in cholesterol metabolism. Whereas cholesterol and statins regulated both LDLR and PCSK9 in a coordinated manner, BBR acted to down-regulate the transcription of PCSK9 while up-regulating LDLR mRNA level post-transcriptionally. This investigation led us to uncover a novel transcriptional regulatory network that modulated the expression of PCSK9, a promising new therapeutic target in LDL-C metabolism.
###end p 67
###begin p 68
###xml 199 201 199 201 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B40">40</xref>
###xml 321 326 321 326 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PCSK9</italic>
###xml 458 460 458 460 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B41">41</xref>
###xml 462 464 462 464 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B42">42</xref>
###xml 635 637 635 637 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B37">37</xref>
###xml 637 637 637 637 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B38"/>
###xml 638 640 638 640 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B39">39</xref>
###xml 693 698 693 698 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PCSK9</italic>
###xml 781 786 781 786 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PCSK9</italic>
###xml 861 863 861 863 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B19">19</xref>
###xml 1088 1093 1088 1093 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PCSK9</italic>
###xml 1173 1175 1173 1175 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B21">21</xref>
###xml 1313 1318 1313 1318 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PCSK9</italic>
###xml 1334 1336 1334 1336 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B21">21</xref>
###xml 1436 1441 1436 1441 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PCSK9</italic>
###xml 1744 1749 1740 1745 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PCSK9</italic>
PCSK9, a recently discovered serine protease important in regulating the degradation of LDLR protein, is a new addition to the list of more than 30 genes whose transcription is controlled by SREBPs (40). When intracellular cholesterol levels are depleted, the mature SREBP translocates to the nucleus, where it activates PCSK9 and other genes' transcription by direct binding to nonpalindromic 9-bp sterol response elements in the promoter/enhancer regions (41, 42). Although in many cases, the key SRE motifs are adjacent to Sp1 or NF-Y binding sites and SREBPs work in concert with these coactivators to induce full transactivation (37-39), findings from our current study indicate that the PCSK9 promoter is rather unique in this aspect. Despite the initial characterization of PCSK9 promoter that identified putative NF-Y and Sp1 sites upstream of the SRE (19), both sequence motifs were later shown to not be critical for SRE function. The NF-Y site (-613) resides 5' outside the functional proximal promoter region, whereas mutation of the Sp1 site (-430) modestly attenuated basal PCSK9 promoter activity in a manner that was not associated with sterol suppression (21) or berberine inhibition (present study). Additional putative Sp1 sites downstream of SRE also failed to exhibit a significant impact on PCSK9 transcription (21). These observations raised an important question as to what was the SREBP cofactor in controlling PCSK9 transcription. In this current study, by conducting several different lines of investigation, we provided solid evidence to demonstrate that the HNF1 binding site adjacent to SRE is the critical regulatory sequence motif and HNF1alpha is the predominant working partner for SREBP2 in the regulation of PCSK9 gene in the context of HepG2 cells.
###end p 68
###begin p 69
###xml 165 167 153 155 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B19">19</xref>
###xml 271 276 259 264 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PCSK9</italic>
###xml 399 404 375 380 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PCSK9</italic>
###xml 517 522 493 498 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PCSK9</italic>
###xml 678 683 654 659 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PCSK9</italic>
###xml 1049 1051 1018 1020 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B32">32</xref>
###xml 1053 1055 1022 1024 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B33">33</xref>
###xml 1161 1163 1130 1132 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B34">34</xref>
###xml 2158 2163 2094 2099 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PCSK9</italic>
###xml 2479 2484 2408 2413 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PCSK9</italic>
###xml 2623 2628 2549 2554 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PCSK9</italic>
###xml 2690 2695 2616 2621 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PCSK9</italic>
###xml 3062 3067 2974 2979 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PCSK9</italic>
###xml 3182 3186 3094 3098 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Hnf1</italic>
###xml 3191 3194 3099 3102 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 3338 3344 3242 3248 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">et al.</italic>
###xml 3425 3430 3329 3334 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PCSK9</italic>
###xml 3545 3549 3445 3449 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Hnf1</italic>
###xml 3554 3557 3450 3453 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 3617 3619 3510 3512 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B43">43</xref>
###xml 3724 3729 3614 3619 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PCSK9</italic>
###xml 142 147 <span type="species:ncbi:9606">human</span>
###xml 149 154 <span type="species:ncbi:10090">mouse</span>
###xml 160 163 <span type="species:ncbi:10116">rat</span>
###xml 3419 3424 <span type="species:ncbi:10090">mouse</span>
It was previously reported that Sp1 and SRE sites, separated by approximately75 bp were perfectly conserved in the PCSK9 proximal promoter of human, mouse, and rat (19). In this study, we show that the HNF1 site residing between Sp1 and SRE is also 100% preserved in the PCSK9 promoter of these three species. This underscores the importance of this approximately100 bp proximal promoter region for PCSK9 gene transcription. Our promoter analysis revealed that deletion or mutation of this HNF1 site severely reduced PCSK9 promoter activity to levels even below those observed with the SRE mutation. Mutation of the HNF1 site also significantly mitigated the transactivation of PCSK9 promoter by nuclear SREBP2 through SRE, suggesting that these two sites work in concert. The liver-enriched trans-activator HNF1alpha shares dimerization and homeodomains with its related protein HNF1beta and mediates sequence-specific DNA binding through the recognition of its cognate sequence 5'-GTTAATNATTAAC-3' located in promoter regions of the target genes (32, 33). The PCSK9-HNF1 site (GTTAATGTTTAAT) shares 11 of 13 nucleotide identities with the consensus sequence (34). To identify the proteins interacting with the PCSK9-HNF1 promoter region, we combined approaches of EMSA, ChIP, siRNA knockdown, and exogenous overexpression. Nuclear extracts of HepG2 cells formed two discrete complexes with the labeled probe of PCSK9-HNF1. Both complexes were supershifted with anti-HNF1alpha antibody, indicating HNF1alpha was a major protein in these complexes. These complexes also modestly reacted with anti-HNF1beta antibody as evidenced by a weak supershifted band. At present, we could not conclude whether the major complex represented the homodimer of HNF1alpha and the minor one was composed of HNF1alpha and HNF1beta as a heterodimer. Further experiments are required to clearly define the protein components within these complexes. A stronger binding of HNF1alpha compared with HNF1beta in intact HepG2 cells was also detected by ChIP assays. Taken together, these results firmly demonstrate the specific binding of HNF1alpha to this newly defined HNF1 site on PCSK9 promoter. The functional importance of this interaction is demonstrated by our siRNA transfection studies. Depletion of HNF1alpha by siRNA transfection reduced the promoter activity, endogenous mRNA, and protein expression of PCSK9 to near background levels. In comparison, siHNF1beta transfection modestly reduced PCSK9 promoter activity and mRNA expression, and caused a small reduction in PCSK9 protein expression. The less significant role of HNF1beta on PCSK9 transcription is further demonstrated by a small increase in PCSK9 promoter activity in HepG2 cells after transfection of pTS-HNF1beta as compared with a substantial increase seen in pTS-HNF1alpha-transfected cells. Based upon these results we conclude that HNF1alpha is the major form of HNF1 factors that interacts with PCSK9-HNF1 site under our experimental conditions. It is possible that HNF1beta may have a significant role in PCSK9 transcription in a different cellular context. Recently, in an integrated study of analysis of mRNA expression in Hnf1alpha-/- pancreatic islets and liver with a computational and experimental identification of HNF1alpha target genes, by conducting ChIP assays Servitja et al. showed that a promoter region containing a putative HNF1 binding motif of mouse PCSK9 gene was occupied by HNF1alpha in hepatocytes isolated from wild-type liver, whereas in hepatocytes isolated from Hnf1alpha-/- liver, HNF1beta was found to bind to this promoter region (43). This observation is consistent with our speculation that HNF1beta could have a compensational role in PCSK9 transcription under certain circumstances.
###end p 69
###begin p 70
###xml 179 181 179 181 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B44">44</xref>
###xml 183 185 183 185 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B45">45</xref>
###xml 342 347 342 347 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PCSK9</italic>
###xml 1669 1671 1649 1651 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B27">27</xref>
###xml 1673 1675 1653 1655 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B46">46</xref>
###xml 1718 1725 1698 1705 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 1727 1729 1707 1709 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B27">27</xref>
###xml 1731 1733 1711 1713 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B29">29</xref>
Since the discovery of PCSK9 and its implication in plasma LDL-C metabolism, different strategies have been explored to block the function of PCSK9 and its interaction with LDLR (44, 45). In this study, through elucidation of the mechanism of BBR-mediated suppression of PCSK9 we provide new evidence to support the notion that inhibition of PCSK9 expression at the transcriptional level by small molecules could be a viable means to increase LDLR expression and to minimally complement and potentially synergize with statin therapy. We showed that BBR inhibits PCSK9 mRNA and protein expression and counteracts the inducing effects of various statins. We have shown at the promoter level the inhibitory effect of BBR was partially abolished by each single mutation of SRE or HNF1 site; this led us to speculate that somehow BBR affected interactions of both SREBP and HNF1 factors to their recognition sequences. By Western blotting we showed that the amount of HNF1alpha was approximately60% less in BBR-treated cells compared with control. Similarly, the abundance of SREBP2 was modestly reduced by BBR treatment. In contrast to the moderate reductions of SREBP2 and HNF1alpha, the diminution of PCSK9 protein expression by BBR was pronounced. These data imply a synergistic effect occurred in BBR-treated cells by down-regulation of each transcription factor at modest levels. This observed synergy would be beneficial with regard to LDLR expression, because SREBP2 is absolutely required for LDLR transcription, and a strong inhibition of SREBP2 would eventually shut down LDLR expression. The facts that BBR treatment increases LDLR protein level in HepG2 cells (27, 46) and in livers of hyperlipidemic hamsters in vivo (27, 29) suggest that the balanced effects of BBR are in favor of LDLR expression and stability.
###end p 70
###begin p 71
###xml 12 18 12 18 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F8">Fig. 8</xref>
###xml 151 156 151 156 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PCSK9</italic>
###xml 328 333 324 329 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PCSK9</italic>
###xml 372 377 368 373 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PCSK9</italic>
###xml 604 609 596 601 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PCSK9</italic>
In summary (Fig. 8), we have identified a highly conserved HNF1 binding site located between SRE and Sp1 site as a critical cis-regulatory sequence of PCSK9 promoter. Our data suggest that the liver-enriched transcription factor HNF1alpha is the principal form of HNF1 factors that binds to the HNF1 sequence motif to stimulate PCSK9 transcription. Whereas statins induce PCSK9 transcription by enhancing the binding of SREBP2 to SRE-1, BBR lowers the cellular abundance of HNF1alpha and SREBP2, resulting in reduced interaction of these two critical trans-activators with their recognition sequences of PCSK9 promoter and leading to a transcriptional repression. These findings may provide novel insights into developing small molecule inhibitors of PCSK9 to improve the efficacy of statins in even further reducing LDL-C by overcoming one of the feedback loops that limits LDLR expression and longevity.
###end p 71
###begin p 72
###xml 19 24 19 24 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PCSK9</italic>
###xml 0 132 0 132 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Depiction of human <italic>PCSK9</italic> promoter and its regulation by statin and BBR through the cis-regulatory elements and trans-acting factors.</bold>
###xml 137 146 137 146 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">plus sign</italic>
###xml 210 215 210 215 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PCSK9</italic>
###xml 257 267 257 267 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">minus sign</italic>
###xml 13 18 <span type="species:ncbi:9606">human</span>
Depiction of human PCSK9 promoter and its regulation by statin and BBR through the cis-regulatory elements and trans-acting factors. The plus sign indicates that statin induces SREBP2 to bind SRE-1 site of the PCSK9 promoter to stimulate transcription. The minus sign indicates the dual effects of BBR in reducing the binding of HNF1alpha to HNF1 site and the binding of SREBP2 to SRE-1 site.
###end p 72
###begin p 73
This work was supported, in whole or in part, by National Institutes of Health Grants 1RO1 AT002543-01A1 and 1R21AT003195-01A2 from NCCAM. This work was also supported by the Department of Veterans Affairs (Office of Research and Development, Medical Research Service).
###end p 73
###begin p 74
###xml 28 33 28 33 <term xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="G1">PCSK9</term>
###xml 33 78 33 78 <p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" textid="75">proprotein convertase subtilisin/kexin type 9</p>
###xml 33 78 33 78 <def xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><p textid="75">proprotein convertase subtilisin/kexin type 9</p></def>
###xml 28 78 28 78 <def-item xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><term id="G1">PCSK9</term><def><p textid="75">proprotein convertase subtilisin/kexin type 9</p></def></def-item>
###xml 78 81 78 81 <term xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="G2">BBR</term>
###xml 81 90 81 90 <p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" textid="76">berberine</p>
###xml 81 90 81 90 <def xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><p textid="76">berberine</p></def>
###xml 78 90 78 90 <def-item xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><term id="G2">BBR</term><def><p textid="76">berberine</p></def></def-item>
###xml 90 94 90 94 <term xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="G3">EMSA</term>
###xml 94 130 94 130 <p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" textid="77">electrophoretic mobility shift assay</p>
###xml 94 130 94 130 <def xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><p textid="77">electrophoretic mobility shift assay</p></def>
###xml 90 130 90 130 <def-item xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><term id="G3">EMSA</term><def><p textid="77">electrophoretic mobility shift assay</p></def></def-item>
###xml 130 135 130 135 <term xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="G4">HDAC1</term>
###xml 135 156 135 156 <p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" textid="78">histone deacetylase 1</p>
###xml 135 156 135 156 <def xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><p textid="78">histone deacetylase 1</p></def>
###xml 130 156 130 156 <def-item xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><term id="G4">HDAC1</term><def><p textid="78">histone deacetylase 1</p></def></def-item>
###xml 156 160 156 160 <term xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="G5">HNF1</term>
###xml 160 187 160 187 <p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" textid="79">hepatocyte nuclear factor 1</p>
###xml 160 187 160 187 <def xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><p textid="79">hepatocyte nuclear factor 1</p></def>
###xml 156 187 156 187 <def-item xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><term id="G5">HNF1</term><def><p textid="79">hepatocyte nuclear factor 1</p></def></def-item>
###xml 187 190 187 190 <term xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="G6">LDL</term>
###xml 190 213 190 213 <p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" textid="80">low density lipoprotein</p>
###xml 190 213 190 213 <def xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><p textid="80">low density lipoprotein</p></def>
###xml 187 213 187 213 <def-item xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><term id="G6">LDL</term><def><p textid="80">low density lipoprotein</p></def></def-item>
###xml 213 218 213 218 <term xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="G7">LDL-C</term>
###xml 218 233 218 233 <p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" textid="81">LDL-cholesterol</p>
###xml 218 233 218 233 <def xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><p textid="81">LDL-cholesterol</p></def>
###xml 213 233 213 233 <def-item xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><term id="G7">LDL-C</term><def><p textid="81">LDL-cholesterol</p></def></def-item>
###xml 233 237 233 237 <term xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="G8">LDLR</term>
###xml 237 249 237 249 <p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" textid="82">LDL receptor</p>
###xml 237 249 237 249 <def xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><p textid="82">LDL receptor</p></def>
###xml 233 249 233 249 <def-item xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><term id="G8">LDLR</term><def><p textid="82">LDL receptor</p></def></def-item>
###xml 249 253 249 253 <term xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="G9">LPDS</term>
###xml 253 279 253 279 <p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" textid="83">lipoprotein-depleted serum</p>
###xml 253 279 253 279 <def xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><p textid="83">lipoprotein-depleted serum</p></def>
###xml 249 279 249 279 <def-item xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><term id="G9">LPDS</term><def><p textid="83">lipoprotein-depleted serum</p></def></def-item>
###xml 279 282 279 282 <term xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="G10">SRE</term>
###xml 282 305 282 305 <p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" textid="84">sterol response element</p>
###xml 282 305 282 305 <def xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><p textid="84">sterol response element</p></def>
###xml 279 305 279 305 <def-item xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><term id="G10">SRE</term><def><p textid="84">sterol response element</p></def></def-item>
###xml 305 310 305 310 <term xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="G11">SREBP</term>
###xml 310 329 310 329 <p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" textid="85">SRE-binding protein</p>
###xml 310 329 310 329 <def xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><p textid="85">SRE-binding protein</p></def>
###xml 305 329 305 329 <def-item xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><term id="G11">SREBP</term><def><p textid="85">SRE-binding protein</p></def></def-item>
###xml 329 334 329 334 <term xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="G12">siRNA</term>
###xml 334 356 334 356 <p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" textid="86">small interference RNA</p>
###xml 334 356 334 356 <def xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><p textid="86">small interference RNA</p></def>
###xml 329 356 329 356 <def-item xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><term id="G12">siRNA</term><def><p textid="86">small interference RNA</p></def></def-item>
###xml 356 359 356 359 <term xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="G13">FBS</term>
###xml 359 377 359 377 <p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" textid="87">fetal bovine serum</p>
###xml 359 377 359 377 <def xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><p textid="87">fetal bovine serum</p></def>
###xml 356 377 356 377 <def-item xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><term id="G13">FBS</term><def><p textid="87">fetal bovine serum</p></def></def-item>
###xml 377 381 377 381 <term xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="G14">ChIP</term>
###xml 381 411 381 411 <p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" textid="88">chromatin immunoprecipitation.</p>
###xml 381 411 381 411 <def xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><p textid="88">chromatin immunoprecipitation.</p></def>
###xml 377 411 377 411 <def-item xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><term id="G14">ChIP</term><def><p textid="88">chromatin immunoprecipitation.</p></def></def-item>
###xml 28 411 28 411 <def-list xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><def-item><term id="G1">PCSK9</term><def><p textid="75">proprotein convertase subtilisin/kexin type 9</p></def></def-item><def-item><term id="G2">BBR</term><def><p textid="76">berberine</p></def></def-item><def-item><term id="G3">EMSA</term><def><p textid="77">electrophoretic mobility shift assay</p></def></def-item><def-item><term id="G4">HDAC1</term><def><p textid="78">histone deacetylase 1</p></def></def-item><def-item><term id="G5">HNF1</term><def><p textid="79">hepatocyte nuclear factor 1</p></def></def-item><def-item><term id="G6">LDL</term><def><p textid="80">low density lipoprotein</p></def></def-item><def-item><term id="G7">LDL-C</term><def><p textid="81">LDL-cholesterol</p></def></def-item><def-item><term id="G8">LDLR</term><def><p textid="82">LDL receptor</p></def></def-item><def-item><term id="G9">LPDS</term><def><p textid="83">lipoprotein-depleted serum</p></def></def-item><def-item><term id="G10">SRE</term><def><p textid="84">sterol response element</p></def></def-item><def-item><term id="G11">SREBP</term><def><p textid="85">SRE-binding protein</p></def></def-item><def-item><term id="G12">siRNA</term><def><p textid="86">small interference RNA</p></def></def-item><def-item><term id="G13">FBS</term><def><p textid="87">fetal bovine serum</p></def></def-item><def-item><term id="G14">ChIP</term><def><p textid="88">chromatin immunoprecipitation.</p></def></def-item></def-list>
###xml 365 371 <span type="species:ncbi:9913">bovine</span>
The abbreviations used are: PCSK9proprotein convertase subtilisin/kexin type 9BBRberberineEMSAelectrophoretic mobility shift assayHDAC1histone deacetylase 1HNF1hepatocyte nuclear factor 1LDLlow density lipoproteinLDL-CLDL-cholesterolLDLRLDL receptorLPDSlipoprotein-depleted serumSREsterol response elementSREBPSRE-binding proteinsiRNAsmall interference RNAFBSfetal bovine serumChIPchromatin immunoprecipitation.
###end p 74
###begin p 75
proprotein convertase subtilisin/kexin type 9
###end p 75
###begin p 76
berberine
###end p 76
###begin p 77
electrophoretic mobility shift assay
###end p 77
###begin p 78
histone deacetylase 1
###end p 78
###begin p 79
hepatocyte nuclear factor 1
###end p 79
###begin p 80
low density lipoprotein
###end p 80
###begin p 81
LDL-cholesterol
###end p 81
###begin p 82
LDL receptor
###end p 82
###begin p 83
lipoprotein-depleted serum
###end p 83
###begin p 84
sterol response element
###end p 84
###begin p 85
SRE-binding protein
###end p 85
###begin p 86
small interference RNA
###end p 86
###begin p 87
###xml 6 12 <span type="species:ncbi:9913">bovine</span>
fetal bovine serum
###end p 87
###begin p 88
chromatin immunoprecipitation.
###end p 88
###begin title 89
REFERENCES
###end title 89

